UB Paderborn / Katalog / Suche / in CDI

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

The Lancet (British edition), 2014-01, Vol.383 (9911), p.31-39

2014

Volltextzugriff (PDF)

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer

Journal of clinical oncology, 2017-07, Vol.35 (20), p.2279-2287

2017

Volltextzugriff (PDF)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

The Lancet (British edition), 2007-07, Vol.370 (9582), p.143-152

2007

Volltextzugriff (PDF)

Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression

Scientific reports, 2020-06, Vol.10 (1), p.9251-9251, Article 9251

2020

Volltextzugriff (PDF)

A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response

Clinical cancer research, 2007-10, Vol.13 (19), p.5869-5875

2007

Volltextzugriff (PDF)

Hazards of Using Masking Protocols When Performing Ligand Binding Assays: Lessons From the Sigma-1 and Sigma-2 Receptors

Frontiers in pharmacology, 2020-03, Vol.11, p.309-309

2020

Volltextzugriff (PDF)

Hepatic drug targeting: Phase I evaluation of polymer-bound Doxorubicin

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1668-1676

2002

Volltextzugriff (PDF)

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

European journal of cancer (1990), 2014-01, Vol.50 (2), p.320-331

2014

Volltextzugriff (PDF)

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer

International journal of oncology, 2009-06, Vol.34 (6), p.1629-1636

2009

Volltextzugriff (PDF)

Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer

Cancer chemotherapy and pharmacology, 2018-07, Vol.82 (1), p.77-86

2018

Volltextzugriff (PDF)

Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1668-1676

Seymour, L. W.

2002

Volltextzugriff (PDF)

The functional purification of P-glycoprotein is dependent on maintenance of a lipid–protein interface

Biochimica et biophysica acta, 1997-09, Vol.1328 (2), p.109-124

1997

Volltextzugriff (PDF)

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

European journal of cancer (1990), 2015-01, Vol.51 (1), p.18-26

2015

Volltextzugriff (PDF)

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

Cancer chemotherapy and pharmacology, 2008-03, Vol.61 (3), p.435-441

2008

Volltextzugriff (PDF)

Outcomes in Patients with Acute Non–Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy

The New England journal of medicine, 1998-06, Vol.338 (25), p.1785-1792

1998

Volltextzugriff (PDF)

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

Journal of controlled release, 1999-02, Vol.57 (3), p.281-290

1999

Volltextzugriff (PDF)

Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition

Clinical cancer research, 1996-04, Vol.2 (4), p.659-668

1996

Volltextzugriff (PDF)

Mitral A velocity wave transit time to the outflow tract as a measure of left ventricular diastolic stiffness. Hemodynamic correlations in patients with coronary artery disease

Circulation (New York, N.Y.), 1994-02, Vol.89 (2), p.553-557

1994

Volltextzugriff (PDF)

Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3505-3505

2012

Volltextzugriff (PDF)

Comparison Based on Age of Baseline Electrocardiographic Abnormalities in Non-Q-Wave Myocardial Infarction

Journal of the American Geriatrics Society (JAGS), 1999-07, Vol.47 (7), p.870-872

1999

Volltextzugriff (PDF)

Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG)

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.6-6

2013

Volltextzugriff (PDF)

Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer

Journal of clinical oncology, 1998-08, Vol.16 (8), p.2761-2769

1998

Volltextzugriff (PDF)

Determination of quercetin in human plasma using reversed-phase high-performance liquid chromatography

Journal of chromatography. B, Biomedical applications, 1995-04, Vol.666 (1), p.149-155

1995

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression

A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response

Hazards of Using Masking Protocols When Performing Ligand Binding Assays: Lessons From the Sigma-1 and Sigma-2 Receptors

Hepatic drug targeting: Phase I evaluation of polymer-bound Doxorubicin

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer

Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer

Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin

The functional purification of P-glycoprotein is dependent on maintenance of a lipid–protein interface

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

Outcomes in Patients with Acute Non–Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition

Mitral A velocity wave transit time to the outflow tract as a measure of left ventricular diastolic stiffness. Hemodynamic correlations in patients with coronary artery disease

Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen

Comparison Based on Age of Baseline Electrocardiographic Abnormalities in Non-Q-Wave Myocardial Infarction

Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG)

Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer

Determination of quercetin in human plasma using reversed-phase high-performance liquid chromatography

Suchergebnisse filtern